"High school entrance examination" results of the pharmaceutical industry under the epidemic
More than half of the company expects to be profitable 3/4
The sudden new crown pneumonia epidemic has affected all walks of life to a certain extent. Although the epidemic has certain benefits for the pharmaceutical industry, compared with the same period last year, the entire industry has also experienced a significant decline.
According to ifind data, among the 126 listed pharmaceutical companies that have disclosed semi-annual performance forecasts, half of the companies are pre-happy, and three-quarters of the companies are profitable. In terms of subdivisions, biological products have become a new frontier for development, and the median increase in corporate net profit has exceeded the traditional strong traditional Chinese medicine and chemical pharmaceutical sectors.
30 companies double their profits
In the first half of 2020, the sudden outbreak of new crown pneumonia put the pharmaceutical industry on the verge of accelerated development, as can be seen from the semi-annual report of the pharmaceutical industry.
According to ifind data, among the 126 pharmaceutical stocks that have disclosed semi-annual performance forecasts, nearly half of the companies are pre-happy, including 40 companies with a forecast increase, 18 with a slight increase, 3 with continued profitability, and 3 with a loss.
Several companies are happy and a few are worried, 29 companies are expected to reduce their performance, and 33 companies lose money. Among them, Meinian Health has a huge loss of 650 million yuan to become the "loss king". The profits of 4 companies including ST Tiansheng, International Medicine, and Yihua Health declined by more than 100%. Qianshan Pharmaceutical Machinery even received the Shenzhen Stock Exchange's decision on the termination of the company's stock listing.
From the perspective of profitability, three-quarters of the companies are profitable. Among them, the "medical equipment brother" Mindray Medical has become the "profit king" of A-share pharmaceutical stocks with a net profit of 3.5 billion yuan. The profit of 30 companies has increased by more than 100%. Intech, Oriental Bio, and Daan Gene are leading the way, and their net profits have increased by 28 times, 13 times, and 12 times respectively.
On the whole, the entire pharmaceutical sector in the first half of the year still ushered in the development trend and won the favor of the capital market. In the first half of 2020, the pharmaceutical industry rose by 50%, outperforming the Shanghai Index by 52%.
Pershing Securities pointed out that in recent years, under the trend of aging population, the boom of medicine as a necessity has continued to rise, coupled with the sudden epidemic in the first half of the year, the entire pharmaceutical industry chain has been on the forefront of accelerated development. Driven by the tuyere, the fundamentals of the entire pharmaceutical sector are improving, making the capital market expected to form a resonance between performance and valuation, which will become the focus of capital gathering for warmth.
Kanghua Biotech becomes the "most expensive" pharmaceutical stock
In terms of segmentation, biological products are the most eye-catching due to the overall profitability of star stocks. In the first half of this year, with the overall decline in net profits in the traditional most profitable Chinese medicine and chemical pharmaceutical industries, the median net profit growth of biological products companies reached 30%.
Individual stocks in the field are even more outstanding. The recent listings of Kanghua Biological and Ganli Pharmaceuticals have been full of profitability, earning 260,000 yuan and 200,000 yuan respectively in the first lottery.
Kanghua Biotechnology is the first and only vaccine manufacturer in China that produces human diploid cell rabies vaccine. After listing, it cut 20 daily limit and replaced Changchun Hi-tech as the "most expensive" pharmaceutical stock. The semi-annual report of Kanghua Biology shows that its net profit in the first half of the year increased by 118%, ranking second in the entire biological products industry, with an estimated net profit of 185 million yuan.
Known as "Moutai in Insulin", Ganli Pharmaceuticals gained 12 consecutive shares after listing, with a market value of hundreds of billions. The semi-annual report shows that the company's performance has increased slightly, and the net profit has increased by 15%, which is expected to be as high as 300 million yuan.
Bright medical device performance
A segment that also deserves attention and has more stocks and is more universal is medical devices. The overall performance of the sector is improving. Among the 42 companies that issued performance forecasts, 26 companies have pre-increased, 2 continued to win, 1 turned losses, and only 4 lost money.
From the perspective of industry leaders, the best-performing stocks in pharmaceutical stocks include "profit king" Mindray Medical and "net profit growth king" Incorporated Medical, all from the medical device field.
Mindray Medical’s high net profit is inseparable from the background of the new crown pneumonia outbreak. Looking at the global epidemic, the demand for monitors, ventilators, and infusion pumps has increased significantly, which fits the business scope of Mindray Medical. At present, the total market value of Mindray Medical has exceeded 400 billion yuan.
"Net profit growth" Wang Yingke Medical's net profit is expected to reach 2.1 billion yuan. The good performance has also allowed the company to usher in an outstanding performance in the A-share market. As of July 15, Intech Medical has increased by more than 1,000% this year, becoming the first non-technological innovation board "10 times" this year.